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Abstract
The molecular and cellular processes that lead to renal damage and to the heterogeneity of lupus 
nephritis (LN) are not well understood. We applied single-cell RNA sequencing (scRNA-seq) to 
renal biopsies from patients with LN and evaluated skin biopsies as a potential source of 
diagnostic and prognostic markers of renal disease. Type I interferon (IFN) response signatures in 
tubular cells and in keratinocytes distinguished patients with LN from healthy control subjects. 
Moreover, a high IFN response signature and fibrotic signature in tubular cells were each 
associated with failure to respond to treatment. Analysis of tubular cells from patients with 
proliferative, membranous, and mixed LN indicated pathways relevant to inflammation and 
fibrosis, which offer insight into their histological differences. In summary, we applied scRNA-seq 
to LN to deconstruct its heterogeneity and identify novel targets for personalized approaches to 
therapy.
Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease that can affect 
multiple organs including the heart, brain, skin, lungs, and kidneys. SLE is characterized by 
the production of autoreactive antibodies against nuclear antigens such as 
ribonucleoproteins, dsDNA, and histones1. Lupus nephritis (LN) affects ~50% of patients 
with SLE and is a major contributor to mortality and morbidity2. Although the exact 
pathogenesis has yet to be fully characterized, immune complex deposition in and along the 
glomerular basement membrane and in the mesangial matrix, with secondary inflammation 
and proliferation of mesangial and endothelial cells, are hallmarks of the disease. 
Additionally, hypercellularity of mesangial and endothelial cells, as well as interstitial and 
glomerular fibrosis, are common features of chronicity and disease progression.
These immune, inflammatory, and parenchymal cell proliferative responses of LN have 
visible and heterogeneous histopathologic manifestations, which can be monitored by renal 
biopsy and evaluated according to the International Society of Nephrology/Renal Pathology 
Society (ISN/RPS) 2003 Lupus Nephritis Classification System3. The spectrum of 
glomerular pathology is variable not only between patients, but frequently within the same 
patient. Moreover, neither initial clinical manifestations nor treatment responses uniformly 
correlate with the histologic class of glomerular injury. Thus, clinical findings and biopsy 
alone are insufficient for accurate prognosis and further measures need to be developed to 
improve treatment and prognostic decisions. Additionally, the molecular basis for the 
observed histopathology is not yet fully characterized and further heterogeneity may exist, 
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which could explain the difficulty in accurately predicting response to treatment. For 
instance, fibrosis has been associated with poor response to treatment, but the underlying 
mechanisms initiating and promoting fibrosis are not fully understood. A further limitation 
within the ISN/RPS classification system is that histologic analysis is completely based on 
glomerular changes, despite a growing body of literature suggesting that the 
tubulointerstitial space is more predictive of response to therapy and prognosis, with 
infiltrates and fibrosis associated with poor renal outcome4–6.
Other potential and more accessible tissue sites than the kidney could also be exploited to 
obtain tissue for biomarkers of SLE progression7. Discovery of signatures in readily 
accessible tissue such as the skin, which even in non-lesional areas can have 
immunoglobulin deposition at the dermoepidermal junction (referred to as the lupus band 
test) analogous to that seen in the kidney8, would greatly facilitate early diagnosis and 
treatment decisions in a much less invasive manner. A previous study demonstrated an 
interferon signature in the keratinocytes from biopsies of non-lesional non-sun exposed skin 
of patients with LN compared to healthy control subjects9. This provides a rationale for 
using skin as a potential surrogate of renal disease, which could be sampled serially to 
follow response.
Single-cell RNA-sequencing (scRNA-seq) is a transcriptomic technology resolving cell type 
contributions in tissues10,11. This technique has been applied to a number of complex renal 
diseases including renal cell carcinoma12,13 as well as to LN9. When resolved at a cell type 
level, transcriptome analysis yields valuable information regarding intercellular signaling 
responses and cell-type-specific pathways involved in promoting and maintaining LN. Here, 
we applied scRNA-seq to renal biopsies of patients with LN to identify novel clinically 
relevant prognostic markers, uncover intercellular interactions, and elucidate key pathways 
underlying the histological classes of LN.
Results
Samples and data acquisition
A total of 21 renal tissue samples were collected from patients with LN undergoing a 
clinically indicated renal biopsy (Supplementary Table 1). Of these patients, 17 also had a 
skin punch biopsy performed at the time of the renal biopsy. In addition to patients with LN, 
3 biopsy pairs of control skin and renal tissue were obtained from healthy control subjects 
undergoing a nephrectomy for kidney transplant donation. Cell suspensions from skin and 
kidney biopsies of the same patient were loaded into separate compartments present on a 
single chip capturing about 250 cells per tissue type (Fig. 1a). The cells captured per chip 
were sequenced at an approximate depth of 200,000 reads/cell disregarding calibrator spike 
reads. A total of 19,200 wells were sequenced; however, only data originating from 6,041 
wells confirmed by microscopy to contain single cells and resulting in a minimum read 
count of 10,000 were retained for downstream bioinformatics analysis.
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Cell lineage determination
Cell lineage determination was done using a principal component analysis (PCA) and a 
graph-based clustering approach. In an iterative process, we filtered out cells of abnormally 
high or low gene counts indicating doublet cell captures or poor-quality cells, respectively, 
resulting in 4,019 cells entering the final analysis. While mitochondrial cutoffs have been 
employed to set aside dead or dying cells, mitochondrial percentage cutoffs were initially 
developed in blood cells where there is little variation in mitochondrial content across cell 
types. In epithelial cells, we and others have observed mitochondrial content to vary widely 
across cell types, and mitochondrial percent cut-offs suitable for hematopoietic cells were 
deemed inaccurate to determine dead or dying non-immune cells14. Dispersion and mean 
expression values were calculated for each gene to identify highly variable genes, which 
were subjected to PCA, and resulted in 11 significant principal components. Graph-based 
clustering followed by t-Distributed Stochastic Neighbor Embedding (tSNE) was used to 
collapse the principal components into two dimensions and resulted in 6 distinct clusters of 
cell types (Fig. 1b). Differential expression analysis identified mutually exclusive sets of 
genes, which were characteristic of the cell lineage and frequently included established 
markers of particular cell types. The top 30 most differentially expressed markers in each 
cluster are provided in Supplementary Table 2. For example, tubular cells uniquely 
expressed UMOD and SLC12A1, whereas keratinocytes uniquely expressed KRT1 and 
KRT10. Fibroblasts expressed many genes encoding extracellular matrix proteins including 
DCN, whereas endothelial cells distinctly expressed FLT1 and PECAM1. Leukocytes 
expressed distinct myeloid, T cell, and B cell genes (CD14, CD3G, and MZB1, respectively) 
yet appeared as one cell type by tSNE analysis (Fig. 1c–e). Although we did not capture all 
known types of glomerular cell types, mesangial cells were recovered as indicated by high 
expression of their unique marker TAGLN. As anticipated, skin and renal biopsies were 
predominantly keratinocytes and tubular cells, respectively. The residual cell types 
represented smaller percentages and their relative abundance varied widely across samples, 
which is also a feature of clinical biopsies examined by standard diagnostic techniques (Fig. 
1c). The relative contribution of each patient to each cluster is reported in Supplementary 
Table 3, and the patient identifier for each cell in the tSNE plot is depicted in Supplementary 
Fig. 1. The relative numerical representation of cell types within the tissue was also 
estimated by counting cells from the hematoxylin and eosin stained slides used for clinical 
diagnosis, and yielded similar percentages to those identified by PCA and tSNE analysis 
(Supplementary Fig. 2). None of these cell type percentages from either counting method 
correlated with clinical data obtained including activity, chronicity, or biopsy class (data not 
shown).
When averaged together across all renal cells, scRNA-seq expression resembled a bulk 
polyA-mRNA sequenced renal biopsy. Similarly, averaged skin single cells correlated with a 
bulk polyA-mRNA sequenced dissociated skin sample. Although averaged renal single cells 
also correlated with bulk sequenced skin and vice versa, they did so to a lesser extent than 
their originating tissue type (Supplementary Fig. 3).
When the keratinocyte subset identified by the first level of clustering analysis was once 
more subjected to clustering analysis, the presence of a small number of sweat gland cells 
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and melanocytes defined by expression of DCD and MLANA, respectively, became apparent 
(Fig. 2a–d)15,16. These cell types were excluded from participation in downstream 
comparative keratinocyte analysis. Similarly, the group of tubular cells identified by first 
level analysis was composed of various subtypes representative of the distinct nephron 
segments as previously reported (Fig. 3a–d)9. In summary, using graph-based clustering of 
the single-cell transcriptomes we were able to assign lineages to each cell and identify the 
cell types present in the biopsy samples, including both the major epithelial cell populations 
as well as rarer cell populations and cell subtypes.
LN skin and kidney epithelium indicate upregulation of type-I IFN response pathway genes
It has been shown that type-I IFNs are elevated in both human and murine SLE and may 
drive pathogenesis, as IFN levels have been associated with disease flares in LN17. It was 
previously demonstrated in a small cohort of patients that keratinocytes from patients with 
LN show upregulation of IFN responsive genes compared to healthy control subjects9. Here, 
through cumulative distribution function analysis we confirmed this observation in a 
separate and larger cohort of patients and further expanded this finding to tubular cells (Fig. 
4a). Type-I IFN response genes in tubular cells (p = 1.4e-11) and keratinocytes (p = 3.3e-10) 
from patients with LN were significantly higher expressed than those of healthy control 
subjects as indicated by the right-shifted curve of established IFN response genes compared 
to ubiquitously expressed genes (Fig. 4a–b). Using the tubular expression of IFN response 
genes we created an IFN response score for each patient, and found that patients who did not 
respond to treatment had significantly higher (p = 0.04) IFN response scores compared to 
those who were either partial (50% reduction in proteinuria at 6 months post biopsy) or 
complete responders (urine protein-to-creatinine ratio (UPCR) mg/mg < 0.5) (Fig. 4c). The 
IFN response score in keratinocytes significantly correlated with the IFN response score in 
tubular cells (r = 0.61, p = 0.004; Fig. 4d). In contrast, correlations of clinical parameters 
including UPCR at the time of biopsy (p = 0.3), Chronicity Index scores (p = 0.83), and 
Activity Index scores (p = 0.14) with both IFN response scores (Fig. 4e) and clinical 
response status (data not shown) were not significant.
To determine whether scRNA-seq data from kidney biopsy tissue provides more valuable 
information than that obtained by non-invasive means, scRNA-seq analysis was performed 
on peripheral blood mononuclear cells (PBMCs) collected at the time of biopsy, specifically 
4 responders and 4 non-responders. The IFN response scores did not vary as a function of 
the clinical response in any of the identified cell populations including T cells, B cells, 
monocytes, and natural killer (NK) cells (data not shown). In conclusion, IFN response 
scores were elevated in tubular cells and keratinocytes from patients with LN patients 
compared to healthy control subjects, and elevated in tubular cells from patients with LN 
who did not respond to treatment compared to those with favorable therapeutic responses.
Patients non-responsive to treatment demonstrate higher expression of fibrotic 
extracellular matrix proteins as compared to responders
To explore pathways other than those reflective of IFN signaling in patients who did not 
respond to therapy, differential expression analysis was performed on the average tubular 
cell profiles created for each patient. This analysis identified 301 significantly (p < 0.05) 
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differentially regulated genes (Fig. 5a). Enrichment analysis revealed significant (p < 0.001) 
upregulation of genes encoding extracellular matrix (ECM) proteins and ECM-interaction 
proteins, reflective of an active fibrotic pathway in patients that were unresponsive to 
therapy compared to those who responded. A similar expression pattern has been previously 
reported and associated with tubular epithelial-mesenchymal transition (EMT) or tubular 
epithelial hypertrophy, both of which may have implications for progressive renal 
tubulointerstitial fibrosis18–21. Relevant to LN, tubulointerstitial fibrosis is a marker of poor 
prognosis5,6 further supporting the finding of this expression in non-responders. Of clinical 
relevance, this gene signature may be predictive of a fibrotic response before it is measurable 
by standard histopathological assessment since the biopsies of some of these patients did not 
demonstrate fibrosis by typical scoring of tubulointerstitial damage. While it is 
acknowledged that ECM proteins are typically expressed by canonical fibroblasts, the 
cellular subset in this analysis expressed tubular cell markers, but not fibroblast markers 
such as VIM and FSP1 (Fig. 5a), supporting that this observation was not simply due to 
fibroblast contamination. Finally, although it is possible that fibroblasts may also play an 
important role in the fibrotic pathways leading to tubulointerstitial fibrosis and progressive 
renal insufficiency in LN, too few fibroblasts were captured to assess any potential 
differences in the contribution of fibroblasts between groups (data not shown).
Two of the differentially expressed genes identified by pathway analysis as ECM interacting 
proteins, TIMP1 and SERPING, that were upregulated in tubular cells of patients who did 
not respond to treatment, have previously been shown to be pro-fibrotic and associated with 
renal fibrosis22,23. Similarly, upregulation of the complement and coagulation cascades 
including C1S and C1R were also noted in non-responders (Fig. 5b)24.
A similar analysis was applied to the keratinocytes of non-responders and responders to 
assess the possibility of monitoring pathways activated in the epithelium of a tissue distant 
from the site of inflammation. Pathway enrichment analysis on the differentially expressed 
genes from keratinocytes of patients who did not respond to treatment also demonstrated 
upregulation of extracellular matrix (Fig. 5b). These included some overlapping and non-
overlapping collagen genes expressed in the tubular cells; for instance, COL1A1 was 
upregulated in both keratinocytes and tubular cells, but COL17A1 was only upregulated in 
the keratinocytes of non-responders and not the tubular cells. The full list of differentially 
expressed genes from each comparison can be found in Supplementary Table 4.
Using logistic regression analysis on fibrotic genes in the tubular cells, an equation 
predicting response to treatment at 6 months post biopsy was created using genes identified 
as fibrotic markers among the differentially expressed genes between responders and non-
responders. Four genes, COL1A1, COL14A1, COL1A2, and COL5A2 were found to 
significantly explain variance and predict response to treatment with a 92% accuracy and an 
area under the curve (AUC) of 0.96 (Fig. 5c). We compared this signature to previously 
published 3-gene (IL1RAP, NCAM1, FCAR) and 5-gene (IL1RAP, NCAM1, FCAR, 
IL28B, and C7) signatures predicting response to treatment. We found that although these 
signatures were associated with response to treatment in our cohort, they were much less 
robust than the collagen-based signature we identified here with AUCs of 0.8 and 0.8125 
(Supplementary Fig. 4). Similar to the IFN response score, we found that the fibrosis score 
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in keratinocytes correlated with the same score in tubular cells (r = 0.45, p = 0.04; Fig. 5d 
left panel). Correlations between response to treatment and patient demographics (race, 
ethnicity, etc.) were explored, but none were found (data not shown). Similarly, correlations 
between tubular fibrosis scores and UPCR at the time of biopsy (p = 0.94), Chronicity Index 
scores (p = 0.22), and Activity Index scores (p = 0.07) were not significant (Fig. 5d). 
Furthermore, there was no correlation between fibrosis seen by light microscopy and fibrosis 
scores (data not shown). PBMC populations including T cells, B cells, NK cells, and 
monocytes from the same patients showed no expression of extracellular matrix proteins or 
fibrotic markers by scRNA-seq (data not shown). This analysis demonstrated that patients 
who did not respond to treatment had significantly elevated levels of ECM proteins which 
through logistic regression were distilled to a 4-gene signature which could predict response 
to treatment at six months after biopsy.
Fibrotic pathways in kidney may be initiated by infiltrating cell receptor-ligand interactions
Understanding the intercellular networks of communication can help elucidate potential 
targets for therapy in a cell-type-specific manner. scRNA-seq provides a unique starting 
point for deciphering ligand-receptor interactions by resolving gene expression according to 
cell type. Potential engagement of the highest expressed cognate receptors and ligands of 
cell types present in LN skin and kidney are indicated (Fig. 6). Many cells in the kidney 
including tubular cells expressed genes encoding various FGF receptors (FGFRs), such as 
FGFR3, at high levels. FGFs and FGFRs have been implicated in fibrosis in many organs 
including the kidney26. While it has been reported that FGF can be produced by 
epithelium27, in this study FGF13 was expressed at high levels by infiltrating leukocytes, but 
not other renal cell types. Additionally, tubular cells expressed high levels of the gene 
encoding chemokine CCL17 whose receptor CCR1 was expressed within the leukocyte 
population, indicating a potential mechanism for attracting circulating leukocytes into the 
interstitium. Tubular cells also expressed high levels of TNFSF10, potentially signaling to 
leukocytes which expressed the gene encoding its receptor, TNFRSF10A. Similarly, 
keratinocytes expressed high levels of FGFR3, although in the skin the ligand was expressed 
in fibroblasts rather than leukocytes as in the kidney. By examining the cells within the 
leukocyte populations expressing these receptors and ligands and comparing their 
transcriptomic profiles to canonical markers we could further resolve the likely cell types of 
origin, and conclude that FGF13 was expressed by myeloid lineage cells, CCR1 was 
expressed by macrophages which appear to have an M2 phenotype, and TNFSFR10A is 
expressed by B cells (data not shown). A similar approach could be employed for the 
remaining interactions to further resolve the interacting cells of interest.
Tubular cells and keratinocytes from patients with proliferative histologic classes 
compared to membranous class upregulate TNF and type-I IFN response pathways
The molecular basis for different histopathologies in LN is not completely understood. To 
determine if there are specific pathways involved in each class, we performed differential 
expression on tubular cells from patients with proliferative LN (class III or class IV) and 
those with membranous disease (class V). This analysis excluded patients with mixed class 
III/V or IV/V disease. Pathway enrichment analysis of the upregulated genes in proliferative 
class disease revealed increased type-I IFN and TNF family signaling compared with tubular 
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cells from membranous class (Fig. 7). Keratinocytes from patients with proliferative disease 
also showed an upregulation of several pathways, including type-I IFN signaling and antigen 
presentation, compared with keratinocytes from membranous disease (Fig. 7). The full list of 
differentially expressed genes can be found in Supplementary Table 4. Thus, this analysis 
showed that patients with proliferative class LN upregulated several immune related 
pathways in both their tubular cells and keratinocytes which differentiated them from 
patients with membranous class of LN.
Tubular cells from patients with mixed histologic classes upregulate distinct expression 
profiles as compared to membranous or proliferative nephritis
We performed differential expression analysis between membranous and mixed class LN, 
and between proliferative and mixed class LN. There were several differentially expressed 
pathways between membranous and mixed class LN, such as IL-1 signaling which was 
upregulated in mixed versus membranous (Fig. 8a). While there were no upregulated 
pathways in mixed versus proliferative, there were several upregulated pathways in 
proliferative disease including TNFR1 signaling (Fig. 8b). Thus, while mixed class histology 
is commonly considered a simple combination of class III or IV with class V, based on our 
findings it is possible that it represents a distinct class of disease with different pathological 
pathways contributing to the histologic phenotype.
Discussion
In this study, scRNA-seq applied to renal and skin biopsies from patients with LN and 
healthy control subjects identified clinically relevant signatures associated with disease. The 
focus and strength of our analysis were the epithelial cells, which accounted for the majority 
of cells in the kidney. Their pathological potential to promote and contribute to fibrosis 
(resulting in poor prognosis) and their utility as a source of biomarkers were explored. 
Although patient numbers were relatively small when compared to GWAS or other such 
large-scale evaluations, this study provides the largest scRNA-seq database to date, covering 
all major classes of LN, and further including healthy donor kidney reference data.
As previously reported, we discovered an elevated IFN response signature in keratinocytes 
from patients with LN compared to healthy control subjects9, indicative of a systemic 
response to IFN. Furthermore, tubular cells from renal biopsies obtained from patients with 
LN compared to healthy control subjects also showed an elevated IFN response signature 
which correlated with keratinocyte expression. We examined other cell types such as 
fibroblasts, mesangial cells, and endothelial cells, and although the trend was the same, the 
cell numbers were not sufficient to draw meaningful conclusions. While an IFN response 
signature may also have been evident by bulk sequencing, identification of this signature 
specifically in tubular cells required scRNA-seq. Accordingly, this study unambiguously 
identified that tubular cells per se upregulate IFN signature genes, and not just infiltrating 
cells that could display a large enough IFN response to be captured by bulk sequencing 
despite their relative rarity. A signature present and visible in the dominant cell type of the 
biopsy justifies applying bulk RNA-seq or RT-PCR as a routine diagnostic in the clinical 
setting without the need for complicated cell sorting. Moreover, although we have no 
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evidence of causation, the tubular IFN response score at the time of biopsy predicted patient 
response to treatment 6 months after biopsy. The keratinocyte IFN response score did not 
significantly predict response to treatment. This may be explained by a weaker signal than 
that observed in the tubular cells and thus requiring larger numbers to reach significance, 
and/or relate to the tissue contextual dependency of downstream expression of IFN 
stimulated genes.
In addition to the IFN signature, pathways associated with ECM proteins and ECM-
interacting proteins indicative of a fibrotic response were significantly upregulated in the 
tubular cells of non-responder patients. Tubular ECM protein expression has been linked to 
tubular EMT, a process whereby tubular cells differentiate into mesenchymal cells and begin 
secreting large amounts of ECM proteins18,20. Although still a topic of debate, EMT is 
linked to increased interstitial fibrosis and by extension poor prognosis28–30. We did not 
detect putative markers of EMT other than COL1A1 and COL1A2, suggesting that these 
cells may be early in this differentiation pathway29 or the findings represent a separate 
fibrotic pathway, such as tubular epithelial hypertrophy21. Remarkably, this fibrotic gene 
expression was independent of histologic evidence of fibrosis, thus providing an important 
adjunct to clinical evaluation. Including such a diagnostic at the time of biopsy could 
potentially guide the use of more aggressive therapy to control fibrotic scar formation 
leading to organ failure.
Pathways indicative of a fibrotic signature in the tubular cells were also significantly 
upregulated in the keratinocytes of non-responders, and furthermore there was a correlation 
in individual patients between fibrotic scores in tubular cells and keratinocytes. Although the 
4-gene model generated in tubular cells to predict response to treatment was not significant 
in the keratinocytes, this may change with higher throughput and more sensitive technology.
By investigating the receptor-ligand interactions among cell types in the skin and kidney, we 
identified several putative signaling interactions. For instance, interactions were identified 
between infiltrating leukocytes and tubular cells through an FGF receptor, the latter known 
to be involved in fibrotic processes and likely responsible for the upregulation of genes 
encoding ECM and ECM-interacting proteins in the tubular cells of non-responder patients. 
Genes encoding FGF receptors were highly expressed in all resident kidney cells, including 
fibroblasts, endothelial cells, and mesangial cells. Additionally, chemokines produced by 
resident renal cells including tubular cells, endothelial cells, and fibroblasts may be involved 
in the recruitment of inflammatory cells into the kidney. Further validating these interactions 
would be important to address in future in vitro and animal studies. It is anticipated that 
exploring such interactions will be critical to developing novel therapeutic targets, which can 
be employed for disease-state-specific treatment based on molecular diagnosis.
Examining skin and kidney epithelial cells revealed molecular signatures which 
differentiated histological classes of LN. Pathway enrichment analysis and differential 
expression in tubular cells from proliferative versus either mixed or membranous class LN 
indicated an upregulation of genes involved in TNF family signaling. Furthermore, many 
other pathways identified in both skin and kidney differentiated the classes, including type-I 
IFN signaling. Consistent with these results, a previous study using microarray technology 
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and antibody staining demonstrated an IFN signature in class IV but not class I LN tubular 
cells31. Our dataset provides an opportunity to explore these pathways to both improve 
diagnostics and inform the development of novel and potentially class specific therapies.
While our previous scRNA-seq study of renal biopsies using the Fluidigm 96-well platform 
yielded most of the dominant renal cell types, glomerular cells were absent9. Using the 800-
well platform markedly increased cell capture, and importantly allowed for the capture and 
identification of mesangial cell profiles from both healthy control subjects and patients with 
LN. Podocytes, however, were not captured; a further increase in throughput by using next-
generation droplet-based microfluidics, recently shown to provide increased resolution of 
cell types and cell states, may prove necessary to capture this rarer population of cells. These 
latter studies, however, were not performed using very limited biopsy tissue (2–10 mm 
needle core pieces) obtained for clinical decision making, but rather on an excess of tissue 
from whole organs or surgically resected tissues13,32–34. While we could resolve mesangial 
cells, endothelial cells, and fibroblasts, their relatively low abundance limited their ability to 
discriminate between patients and patient groups35. Consequently, our study focused on the 
dominant epithelial cells based on clusters formed of cells from many patients. Since batch 
correction was not performed due to the inherent difficulty in defining a batch when every 
patient’s samples are processed separately, we performed differential expression at the cell 
population level generated through “course” clustering, which by design minimized cell 
cluster formation based on individual patients. Approaches to increase the number of each 
cell type captured will be needed to evaluate the minor cell populations of the skin and 
kidney.
In summary, we have shown that scRNA-seq is feasible and informative in the study of LN, 
despite the marked complexity and heterogeneity of the disease. Our findings support the 
utility of skin biopsies as a potential adjunct in the management of LN since repeat biopsies 
can be performed regularly. scRNA-seq of LN tissues revealed molecular signatures 
clinically relevant to prognosis, which could be used to meaningfully augment the current 
standard of care and better stratify patients. Moreover, these molecular signatures also begin 
to reveal processes which may underlie the histologic heterogeneity of LN.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Cell lineage determination by dimensionality reduction analysis.
a. Schematic of the scRNA-seq pipeline. Skin (n = 17) and kidney (n = 21) samples from 
patients with LN or healthy control subjects (n = 3) were collected at the time of clinically 
indicated renal biopsy or live kidney donation, respectively. Skin and kidney biopsies were 
enzymatically disaggregated into single cell suspensions and loaded onto a microfluidic 
device. b. t-Distributed Stochastic Neighbor Embedding (tSNE) clustering of 4,019 single 
cells. PCA identified six major clusters of cells from both skin and kidney biopsies. Cells are 
color-coded by an algorithm for determining expression clusters and cell types. c. Box plot 
of the percent contribution of each cluster from skin and kidney biopsies. Boxes are colored 
by cluster corresponding to Fig. 1b. The boxes indicate the first quartile, median, and third 
quartile. Whiskers indicate the highest and lowest values. Points were drawn as outliers if 
they were more than 1.5 times the inter quartile range. d. Heatmap of the top 10 most 
differentially expressed genes in each cluster to identify mutually exclusive gene sets, which 
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were then used to determine the cell lineage of each cluster. Each row is a differentially 
expressed gene and each column is a single-cell organized by cluster identity. Transcript 
abundance ranges from low (purple) to high (yellow). e. Violin plot of selected markers 
indicating the expression level of canonical markers within each cluster. Violin plots are 
colored by cell type and width represents the percent of cells expressing the marker at a 
given level in Loge(CPM+1) from 0 to 6.
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Figure 2. Subclustering of keratinocytes reveals two rare skin-specific cell types.
a. tSNE plotting of 1,939 keratinocytes identified in initial clustering analysis colored by 
cluster identifying algorithm with cell type labels next to each cluster. b. Expression of DCD 
and MLANA, markers of the new clusters, within the tSNE plot (n = 1,939 cells) from low 
expression (grey) to high expression (dark blue). c. Heatmap of the differentially expressed 
genes between each identified cluster. d. Violin plot of MLANA and DCD, markers of 
melanocytes (n = 33) and sweat gland cells (n = 29), respectively. Violin plots are colored by 
cell type and width represents the percent of cells expressing the marker at a given level in 
Loge(CPM+1) from 0 to 8.
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Figure 3. Subclustering of tubular cells identifies major tubular cell subtypes of the nephron.
a. tSNE plotting of 1,221 tubular cells identified by initial clustering analysis. Three clusters 
of tubular cells are identified and colored by clustering algorithm with labels of putative 
cluster identity indicated next to each cluster. b. Expression of established tubular subtype 
markers within the tSNE plot (n = 1,221 cells) from low expression (grey) to high 
expression (dark blue). c. Heatmap of the top 10 most differentially expressed genes 
between each cluster. d. Violin plots of UMOD, CALB1, and ALDOB which are canonical 
markers of Loop of Henle (n = 581), distal tubular (n = 394), and proximal tubular cells (n = 
246), respectively. Violin plots are colored by cell type and width represents the percent of 
cells expressing the marker at a given level in Loge(CPM+1) from 0 to 6.
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Figure 4. IFN response signature differentiates patients with LN from healthy control subjects 
and response to treatment.
a. Cumulative distribution function (CDF) of the ratio of expression of 212 IFN responsive 
genes (red line) or ubiquitously expressed genes (black line) in both tubular cells (n = 1,112 
patient cells and n = 109 healthy control cells, p = 1.4e-11) and b. keratinocytes (n = 1,766 
patient cells and n = 173 healthy control cells, p = 3.3e-10) compared using a two-tailed 
Wilcoxon signed rank test. c. Boxplot of IFN response scores in healthy control subjects (n 
=3), patients who responded to treatment (n = 13), and patients who did not respond to 
treatment (n = 5) compared with a two-tailed Student’s t-test (p = 0.0003, t = 4.7234). The 
boxes indicate the first quartile, median, and third quartile. Whiskers indicate the highest and 
lowest values. Points were drawn as outliers if they were more than 1.5 times the inter 
quartile range. d. Pearson’s correlation between tubular and keratinocyte IFN response 
scores per patient (n = 20, r = 0.61, p =0.004). e. Pearson’s correlations between IFN 
response scores and UPCR (p = 0.3), Chronicity (p = 0.83), and Activity indices (p = 0.14).
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Figure 5. A fibrotic gene signature as a potential prognostic marker for patients non-responsive 
to treatment.
a. MA plot of differential expression analysis performed between tubular cells of patients 
responsive (n = 13) or non-responsive to treatment (n = 5). Significantly differentially 
expressed genes determined by the Wald test corrected for multiple comparisons. are colored 
in red. b. Pathway enrichment analysis of genes identified as upregulated in patients non-
responsive to treatment (n = 13) in Figure 5A. -Log10(p-value) determined by gene ontology 
fuzzy-enrichment analysis of each pathway is shown for both keratinocytes and tubular cells 
colored from least significant (black) to most significant (red). Log2 fold change in gene 
expression between patients non-responsive to treatment (n = 13) compared with patients 
responsive to treatment (n = 5) in each pathway are indicated for tubular cells from smallest 
(grey) to highest (orange). c. Receiver operating characteristic curve of the logistic 
regression equation of differentially expressed fibrotic genes, COL1A2, COL1A1, 
COL14A1, COL5A2, with area under the curve (AUC) indicated (n = 18 patients). d. 
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Pearson’s Correlations between the log2 transformed tubular and keratinocyte fibrosis scores 
(n = 20, r = 0.45, p = 0.04), the tubular fibrosis score by biopsy class (p = 0.80, F = 0.334), 
and between tubular fibrosis scores and UPCR (p = 0.94), Chronicity (p = 0.22), and 
Activity indices (p = 0.07). The boxes indicate the first quartile, median, and third quartile. 
Whiskers indicate the highest and lowest values.
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Figure 6. Putative receptor-ligand interactions between kidney and skin cells.
Lines represent interactions between cell types in the skin and the kidney, and are shaded 
according to the ligand expression as detailed in the scale bar. Lines originate at the ligand 
and connect to its receptor as indicated by the arrowhead. Each cell type is color coded and 
represented by that color in each organ. Only the top expressed receptors and ligands with 
expression above 45 CPM and 65 CPM, respectively, within each cell type are shown. 
Receptors and ligand are arranged by expression strength clockwise from lowest expression 
to highest. Ligands or receptors without a cognate pair were excluded from visualization. 
Only patients with LN (n = 18) were included in this analysis.
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Figure 7. Differential expression and pathway enrichment analysis of tubular cells and 
keratinocytes between membranous and proliferative LN.
Significantly enriched pathways in both tubular cells and keratinocytes in membranous (n = 
6) and proliferative (n = 8) LN are indicated. Mixed class III/V or IV/V were excluded from 
this analysis. Color intensity and length of bar indicates higher-Log10(p-value) determined 
by gene ontology fuzzy-enrichment analysis from least significant (white) to most 
significant (red).
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Figure 8. Differential expression and pathway enrichment analysis of tubular cells between 
membranous or proliferative LN and mixed class disease.
a. Differential expression analysis and pathway enrichment of mixed class nephritis (class 
III/V and class IV/V, n = 5) vs. membranous (class V, n = 6). Color intensity and length of 
the bar indicate higher-Log10(p-value) determined using gene ontology fuzzy-enrichment 
analysis from least significant (white) to most significant (red). b. Upregulated pathways and 
genes in proliferative nephritis (class III and class IV, n = 8) vs. mixed class nephritis. -
Log10(p-value) determined using gene ontology fuzzy-enrichment analysis of each pathway 
is shown and colored from least significant (black) to most significant (red).
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